Alpheus Medical Advances Sound-Activated Brain Cancer Therapy Trial

CHANHASSEN, Minn. – April 09, 2026 – Biotechnology firm Alpheus Medical has initiated a pivotal Phase 2b clinical trial for a novel glioblastoma therapy, a significant step forward in the fight against one of the most aggressive and difficult-to-treat brain cancers. The company announced it has already enrolled 10 patients in the randomized controlled study, which will evaluate a non-invasive, drug-centered approach that uses ultrasound to activate a therapeutic agent directly within tumor cells.

The investigational therapy offers a new strategy for a disease where treatment options have seen little progress for decades, leaving patients with a grim prognosis.

Confronting a Formidable Foe

Glioblastoma (GBM) is the most common malignant brain tumor in adults, notorious for its rapid growth and diffuse infiltration into healthy brain tissue. This invasive nature makes complete surgical removal virtually impossible, leading to near-certain recurrence. Even with the current standard of care—a grueling regimen of surgery, radiation, and chemotherapy known as the Stupp protocol—the median survival time for patients is a mere 12 to 15 months.

Key challenges have historically thwarted progress. The brain's protective blood-brain barrier blocks most drugs from reaching their target, and tumors quickly develop resistance to existing treatments like the oral chemotherapy agent temozolomide. While advancements like Tumor-Treating Fields have offered incremental improvements, the five-year survival rate remains below 10%, highlighting what experts describe as a desperate and urgent need for innovation.

"Glioblastoma patients have few effective treatment options and poor long-term outcomes, highlighting the urgent need for innovation," said David Reardon, MD, Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and the study's Principal Investigator.

A New Strategy: Activating Drugs with Sound

Alpheus Medical’s approach, based on Porphyrin Metabolite Activation (PoMA) and also known as Sonodynamic Therapy (SDT), aims to overcome these long-standing hurdles. The treatment involves two key components: a sensitizing agent and low-intensity ultrasound.

Patients first ingest a small molecule, 5-aminolevulinic acid (5-ALA), which the body metabolizes. This process causes a compound, protoporphyrin IX (PpIX), to selectively accumulate in rapidly dividing cancer cells. Neurosurgeons have long used this unique property of 5-ALA to make tumor cells glow under a special light, allowing for more precise surgical resection.

Alpheus's therapy leverages this accumulation for treatment. After the drug has settled in the tumor cells, a non-invasive device applies low-intensity, diffuse ultrasound to the patient’s head. The sound waves activate the PpIX compound, triggering the release of reactive oxygen species—a form of localized oxidative stress that kills the cancer cells from within while sparing surrounding healthy tissue. Because the ultrasound is applied diffusely across the brain hemisphere, the therapy is designed to target the unseen, infiltrative cells that standard treatments miss.

This method has shown significant promise in earlier studies. A previous Phase 1/2 trial in patients with recurrent glioblastoma, a population with even poorer outcomes, demonstrated that SDT more than doubled median overall survival to 15.7 months and tripled progression-free survival to 5.5 months compared to historical benchmarks. The treatment was also well-tolerated, with no serious adverse events related to the therapy.

The Path to Validation: A Closer Look at the Trial

The newly initiated Phase 2b trial (NCT07225621) is designed to provide the rigorous, randomized data needed for potential regulatory approval. The study is expected to enroll over 100 patients with newly diagnosed glioblastoma at up to 15 sites across the United States and Europe. All participants will have already undergone surgery and standard chemoradiation.

In the trial, patients will be randomly assigned to one of two groups. One group will receive the standard of care—adjuvant temozolomide chemotherapy—plus the investigational SDT. The control group will receive the standard of care plus a sham, or placebo, version of the ultrasound therapy. This double-blind design ensures that neither the patients nor their doctors know who is receiving the active treatment, eliminating bias and providing a clear measure of the therapy's true effect.

The primary goal is to measure progression-free survival (PFS), or the length of time patients live without their cancer worsening. Secondary goals include overall survival, safety, and tolerability.

"The Phase 2b trial marks an important step forward in bringing our new therapeutic approach to patients with glioblastoma," said Vijay Agarwal, MD, Chief Executive Officer of Alpheus Medical. "We believe our drug-centered approach has the potential to address the diffuse nature of the disease in ways that localized treatment cannot. With strong early enrollment, we are focused on generating the randomized clinical data to advance this therapy."

Biotech Backing and a Glimmer of Hope

The ambitious trial is supported by significant financial backing, signaling strong investor confidence in the technology's potential. In 2025, Alpheus Medical closed an oversubscribed $52 million Series B financing round co-led by prominent healthcare investors HealthQuest Capital and Samsara BioCapital. The funding syndicate also includes venture arms of leading non-profits like the American Cancer Society and the National Brain Tumor Society, underscoring the alignment between the company's mission and the patient community's needs.

This financial runway is critical for navigating the complex and expensive path of late-stage clinical development. If the Phase 2b trial successfully replicates or improves upon the promising results seen in earlier studies, it could establish a new standard of care for a disease that has been starved of breakthroughs.

For patients and families facing a glioblastoma diagnosis, the initiation of this trial represents more than just a scientific milestone. It signifies a tangible new avenue of hope, a potential shift in the paradigm of how this devastating brain cancer is fought, and a novel strategy designed to attack the disease at its very roots.